BACKGROUND: Previous literature has emphasized the importance of cost sharing, health literacy, socioeconomic status, cognitive function, disease burden, and polypharmacy as some of the determinants of medication adherence. Little research has been published examining disparities in adherence rates when comparing different regions of the United States.
G eographical variation in health care expenditure exists in both commercial and Medicare populations and has been well documented in the literature. [1] [2] [3] [4] These studies focus on variation in inpatient hospitalizations, outpatient medical resource utilization, and overall per capita differences, but typically exclude pharmaceutical expenditure and utilization.
1,2 Very little information exists regarding pharmaceutical utilization and costs across different geographical areas.
In the United States in 2012, approximately 50 million beneficiaries were covered under Medicare, and 165 million beneficiaries were covered under commercial insurance, with an expected increase of millions in 2014 in the commercially insured population from the Affordable Care Act. 5 Medication adherence in both of these populations will have a major impact on the effectiveness of care delivered, especially for chronic conditions. Identifying and quantifying population driven variation inherent in adherence-related quality measures would lead to quality improvements, aligning beneficiary, provider, and payer incentives for optimal therapeutic outcomes and appropriate use of specific pharmaceutical agents. 6 While there may be many underlying reasons for differences in adherence between Medicare and commercial populations, based on demographics, number of medical conditions, and number of concurrent medications, there may also be similarities and correlations that could inform decision making. When evaluating adherence to chronic medications for diabetes, hypertension, and hyperlipidemia, there are guidelines and standards of care that dictate first-line choice of drugs for the management of these conditions. The issues leading to nonadherence that are medication related (e.g., side effects and dosage frequency) may also correlate between the Medicare and commercial populations. [7] [8] [9] However, differences in cost sharing,
Geographic Variation in Medication Adherence in Commercial and Medicare Part D Populations
What is already known about this subject
• Geography plays a significant role in medication adherence to antidiabetics, antihypertensives, and antilipidemics in both a large commercial and Medicare Part D population.
• Quantifying the importance of geography, age, gender, and socioeconomic status empowers payers, providers, and quality organizations to target at-risk populations and set adherence targets for specific patient cohorts.
What this study adds R E S E A R C H
missing eligibility information were excluded from the study. All data were maintained according to Health Insurance Portability and Accountability Act requirements; thus, no institutional review board approval was required.
Calculation of Medication Adherence
For the purposes of this study, antidiabetic medications were defined as sulfonylureas, GLP-1 receptor agonists, biguanides, DPP-4 inhibitors, meglitinide analogues, thiazolidinediones, or any combination of 1 or more of these classes. Beneficiaries using insulin in any of the study years were excluded from the antidiabetic adherence measure in that particular year. Antihypertensive medications were defined as angiotensionconverting enzyme inhibitors, direct renin inhibitors, and angiotensin II-receptor antagonists, or any combination product including one or more of these classes. Antilipidemic medications were defined as HMG CoA reductase inhibitors (statins) or any combination product including a statin. PDC was calculated for each calendar year for each insured beneficiary meeting enrollment and prescription use criteria for that calendar year as previously outlined. PDC was calculated according to methods published by Chu and Kawatkar (2011) . 16 Consistent with these methods, PDC was defined as the number of days covered by medication within the medication type (antidiabetic, antihypertensive, and antilipidemic) divided by the number of days from time of first prescription until date of termination or until December 31 of that year.
Key Variables
In examining the impact of geography, we used 9 U.S. Census designated geographic regions, based on the location of the beneficiary. The East South Central region was designated as the control region in the logistic model. Considering a large mean age difference between commercial and Medicare population, age was used as a categorical variable, with a distinct set of categories for the commercial and Medicare study population. Low-income subsidy (LIS) status was used as a binary variable, where beneficiaries who received LIS anytime during the year were designated as having LIS status. Median household income for the commercial population was obtained from the U.S. Census data and was also used as a categorical variable, with < $25,000 as the lowest level and > $75,000 as the highest category. Out-of-pocket pharmacy expenses for the commercial beneficiaries were calculated as a sum of their coinsurance and copayment for the year. We did not attempt to account for differences in plan design or deductible amounts or use only the cost of the study medications, since the vast majority of these classes have been dominated by low-cost generic drugs since 2010. We did not include the out-ofpocket expense variable in the logistic model for the Medicare beneficiaries because in the LIS population the out-of-pocket amounts are artificially suppressed and are not comparable health literacy, access to care, disease burden, and cognitive function could drive differences in medication adherence as well. [10] [11] [12] In a recent publication, Qato and Trivedi (2013) highlighted the geographic disparities in high-risk medication utilization in the elderly population in the United States. 13 This publication has heightened awareness of the significant variation that can exist when looking at a widely used quality metric across geographic regions. In another recent publication on statin adherence, using data from 2006-2007 prescription claims, Franklin et al. (2013) showed that the adherent populations were more likely to be older, to have a higher income, and to live in the New England region.
14 The study examined adherence using measures such as proportion of days covered (PDC) and group-based trajectory models; however, the focus of the study was not to examine disparities in detail, but to compare the results of group-based trajectory models with the conventional PDC calculation.
This study evaluates geographic variation based on 9 different U.S. Census regions in medication adherence for the 3 aforementioned chronic conditions (diabetes, hypertension, and hyperlipidemia) by a large commercial and Medicare Part D plan, stratified by year and benefit type for a period of 3 years from 2010 to 2012. These chronic conditions were chosen because of the large populations impacted by each, as well as because of their popularity among organizations measuring quality (i.e, Centers for Medicare and Medicaid Services and Pharmacy Quality Alliance). 15 
■■ Methods Overview
This study focused on medication adherence in users of antidiabetic, antihypertensive, and/or antilipidemic medications in a commercially insured and Medicare Part D population. Results for each of these populations are reported separately by year. Beneficiaries who take multiple types of medications (antidiabetic, antihypertensive, and antilipidemic) and/or appear in multiple years appear in the study multiple times.
Data and Identification of Participants
Pharmacy claims and eligibility data were used from a large commercial pharmacy benefits manager and a large Medicare Part D prescription drug plan. For this retrospective cohort study, we enrolled only insured beneficiaries with at least 2 antidiabetic prescription fills, 2 antihypertensive prescription fills, or at least 2 antilipidemic prescription fills in calendar year 2010, 2011, or 2012, and who were enrolled for at least 80% of the given year (9.6 months). Beneficiaries must have been at least 18 years of age at time of enrollment to be included. All demographic information for insured beneficiaries was obtained from enrollment files for the year of study, where age, socioeconomic status, and state of residence were assigned for a year based on the time of enrollment. Beneficiaries with with the non-LIS population. These aggregate copayments thus would not serve as a good proxy for disease burden in the Medicare Part D population.
Statistical Analysis
Frequency distribution with chi-square statistics of the key variables was performed for the Medicare population and the commercial population separately for 2010-2012. For each year, 6 separate multiple logistic regressions were executed to test for the adherence differences in antidiabetic, antihypertensive, and antilipidemic medications for both the commercial and Medicare populations. As previously described, the key variables included in the model were the 9 U.S. regions as defined by the U.S. Census Bureau, as well as age, gender, socioeconomic status (defined by median household income and LIS status), and yearly out-of-pocket pharmacy expenses for the commercial population. Propensity score bin-bootstrapping was used to calculate mean PDC for each medication type in each year in each geographic region in order to adjust for baseline population differences and minimize sample bias. All statistical analysis was completed using SAS 9.2. (SAS Institute, Cary, NC).
■■ Results
The results presented in this section focus only on the 2012 data, but we found similar trends in the 2010 and 2011 data for both the Medicare and commercial study populations. Results from the multiple logistic regression models for years 2010 and 2011 are shown in Appendices A and B (available in online article).
Medicare Part D Population
We identified 447,285 Medicare beneficiaries from the Medicare Part D plan in 2012 who received at least 1 prescription of antidiabetic, antihypertensive, or antilipidemic medications. Of these, we excluded 12 beneficiaries who were missing eligibility information; 23,966 who did not have at least 2 prescriptions of the selected medications; 43,753 who were enrolled less than 80% of the year; and 21 who were less than 18 years of age in 2012. After applying these exclusion criteria, our final Medicare population for 2012 consisted of 379,533 beneficiaries ( Figure 1 ).
Since Medicare consists primarily of the elderly population, we categorized the age variable accordingly. As shown in Table 1 , around 29% of the Medicare population in 2012 is under 65 At least 18 years of age n = 659,553
Final study population n = 379,533
Final study population n = 659,553
Total excluded n = 67,752 (15.1%) Total excluded n = 251,006 (27.6%) a Antidiabetics, antihypertensives, and antilipidemics. Rx = prescription.
years of age, and 68% are female. The geographic region with the greatest representation in the selected Medicare population was the South Atlantic region with 23.7%. The region with the smallest representation was the Pacific region, with about 1.1% of the selected population. Lastly, 70% of the selected Medicare population received LIS, and 30% did not.
Multiple logistic regression performed on the 2012 Medicare population found that the New England region had the most adherent beneficiaries and the West South Central region had the least adherent beneficiaries, when controlling for age, gender, and LIS status. We show in Table 2 that beneficiaries residing in the New England region were found to be 51% more adherent to their antidiabetic medications, 60% more adherent to their antihypertensive medications, and 62% more adherent to their antilipidemic medications than those residing in the East South Central region. Beneficiaries who were younger than 65 years of age were significantly less likely to be adherent in all 3 classes of medications than those who were older than 65 years. Females were significantly less likely to be adherent than males. Beneficiaries who did not have LIS status were significantly more likely to be adherent in all 3 medication classes than those who received LIS (antidiabetic odds ratio 
Commercial Study Population
We applied similar exclusion criteria to the commercial prescription plan side as to the Medicare population. We identified 910,559 beneficiaries in 2012 who received at least 1 antidiabetic, antihypertensive, or antilipidemic medication. Of these 910,559 beneficiaries, we excluded 125,493 as their enrollment was for less than 80% of the year; 35,437 for their missing eligibility information; 85,819 who did not have at least 2 prescriptions of the selected medications; and 4,257 who were younger than 18 years of age. This exclusion resulted in a 2012 commercial study population of 659,553 beneficiaries ( Figure 1 ). Since the commercial population was younger in age, we applied different age categories, with only 13% of the eligible population above 65 years of age, as shown in Table 1 . The female-to-male ratio in the commercial population was different than in the Medicare population, with females comprising only 44% of the commercial study population in 2012. Similar to the Medicare population, we found that around 29% of the selected commercial study population resided in the South Atlantic region in 2012. Only 7% of the commercial study population was found to have spent less than $10 in their out-of-pocket expenses in 2012, where more than half of the total population was found to have paid more than $100 in 2012. As expected, only a small percentage of this population had a median household income less than $25,000. Similar to the previous Medicare results, beneficiaries living in the New England region were found to be significantly more adherent, and those living in the West South Central region were found to be the least adherent to all 3 medications in 2012. As shown in Table 3 , commercial beneficiaries who were residing in the South Atlantic and Pacific regions were significantly less likely to be adherent in all 3 medications than those residing in the East South Central region, with ORs ranging from 0.77 to 0.91 and from 0.86 to 0.99, respectively. Beneficiaries who were under 45 years of age were significantly less likely to be adherent than those who were 45-49 years of age. Beneficiaries aged more than 65 years were twice as likely to be adherent as those 45-49 years of age. Females in the commercial population also were found to be significantly less likely to be adherent than males (OR = 0.72-0.86). Beneficiaries who 
TABLE 2

Multiple Logistic Regression on 2012 Medicare Study Population
impacting the likelihood of beneficiaries being adherent to their medications, we are unaware of a study that has used a nationwide sample to examine geographic variation in adherence rates. We have used multiple years of data and looked across multiple medication classes to strengthen our conclusions.
There appears to be a relationship between geography of beneficiaries and their likelihood of being adherent to their diabetes, hypertension, and hyperlipidemia medications. This correspondence is not surprising, given that geography serves as a proxy for health literacy, care access, burden of disease, race, and other variables that have an established relationship with medication adherence in the literature. What is more surprising perhaps is the consistency of this variation in Medicare and commercial populations across multiple years and across spent greater than $1,000 in out-of-pocket expenses and those who had median household income >$75,000 were significantly more likely to be adherent than those who paid < $10 in outof-pocket expense and those with less than $25,000 median household income.
■■ Discussion
Nonadherence to chronic medications is estimated to cost the U.S. health care system $100-$300 billion annually and to result in 125,000 deaths and 10% of all hospitalizations. [17] [18] [19] This study examined the relationship between readily accessible beneficiary characteristics and medication adherence to antidiabetic, antihypertensive, and antilipidemic medications. While extensive research has been conducted to identify factors (Figure 2 ). The figure depicts the variation in medication adherence observed in the commercial and Medicare populations, after propensity score bin-bootstrapping. Maps produced across years and across medication types showed similar magnitudes of variation and are not shown.
In both populations, socioeconomic status had a significant relationship to adherence, as across all medications and years we saw distinctly higher ORs in higher socioeconomic status beneficiaries. Given the established relationship between education and socioeconomic status, this increase in ORs is not an unexpected result. 20 Especially in the Medicare population, however, where the burdens of copayments are largely removed for the LIS beneficiaries, the difference emphasizes that this population requires support beyond copayment relief. In the commercial population, higher total out-of-pocket medication spend was associated with a higher likelihood of adherence. Drawing any firm conclusions from this data is difficult, given the limitations of the variable, but there is likely some relationship between out-of-pocket spend and the number of comorbid conditions in the commercial population. Thus, those with fewer health problems are likely less engaged in taking their medication exactly as prescribed. This pattern was seen across all medications and all years.
In all medications and across most years in both populations, females had a slight but significantly lower probability of adherence than their male counterparts. This finding is consistent with a growing body of literature showing that females have a lower rate of adherence than males, possibly because females put others before their own health. 10, [21] [22] [23] In the commercial population, older beneficiaries had consistently higher adherence than their younger counterparts. Younger beneficiaries possibly see adherence to their medication as less of a priority than older individuals. [24] [25] [26] In the Medicare population, we see a similar pattern, but that pattern is not significant across all medications and years and is not as pronounced as in the commercial population, especially when looking at groups above the age of 65. Medicare beneficiaries below the age of 65 are often disabled and thus are not comparable to the broader Medicare population. It is important to recognize the challenges to medication adherence for this group of at-risk beneficiaries.
Limitations
This study has several limitations that must be recognized. First, we have only used prescription data from 1 large national insurer for this analysis. While fairly well represented in all regions, age groups, and socioeconomic strata, there is potential for sample bias. In an attempt to minimize this bias, we have used a bootstrapping procedure to verify our results. This procedure creates a relatively homogeneous population across all geographic regions, helping to smooth out adherence variation due to age, gender, socioeconomic status, and multiple medications.
14 In general, the Medicare population showed greater geographic variation than the commercial population, with the greatest OR between 1.601 and 0.966 in the 2012 antihypertensive population. In every year and medication, New England and the West North Central region had the highest likelihood of adherent beneficiaries. In contrast, the East South Central and West South Central regions had the lowest likelihood of adherent beneficiaries across all years and medications in the Medicare population.
Less geographic variation was observed in the commercial population, with an OR between 1.175 and 0.765 in the 2012 antihypertensive population. Again, however, the New England region had the highest ORs across all years and medications, and the West South Central region had the lowest ORs across all years and medications. The results obtained by the logistic regression were confirmed through bootstrapping, where certain regions were oversampled to create a homogenous population in each geographic region to try to remove sample bias. The results of this additional analysis are depicted with the pharmacy out-of-pocket expenses. The current study did not control for comorbidities, as medical claims were not available for the Medicare Part D population. Future work should incorporate this variable, either through medical claims or by using a validated pharmacy claims index. Next, when calculating total out-of-pocket prescription expenses, we did not take into account the percentage of total spend of these adherence medications. Instead we relied on the general assumption that since 2010, branded products in these adherence categories represent a small portion of utilization, and thus spending on adherence prescriptions represents a small portion of overall drug spend. In the Medicare population, we did not differentiate between LIS dual eligible and LIS nondual eligible, as this information was not readily available in our dataset. Further differentiating between these 2 populations may provide more insightful results for policymakers, as the ratio of duals to nonduals often differs from plan to plan. Finally, we have used census data to approximate median household income, which is aggregated by 5-digit ZIP code, and thus this value is not representative of the individual's true household income.
■■ Conclusions
Previous research has demonstrated that the factors that influence medication adherence are complex and numerous. This study has confirmed the fact that readily accessible beneficiary characteristics obtained from prescription drug claims show power in predicting the likelihood of a beneficiary to be adherent to chronic medications for diabetes, hypertension, and hyperlipidemia. The true power of this limited set of variables is unknown and is likely only a small fraction of the total variation seen between beneficiaries with respect to medication adherence. Knowing the relative importance of these variables, however, can empower payers, providers, and quality organizations to better develop interventions for at-risk populations and set adherence targets for populations that do not assume homogeneity of beneficiaries within the population. 
